跳至主要内容
临床试验/NCT02602873
NCT02602873Unknown不适用

Guangzhou Women and Children's Medical Center

Guangzhou Women and Children's Medical Center1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2015年8月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
150
试验地点
1
主要终点
"Genotypes as measured by polymerase chain reaction-restriction fragment length polymorphism"

研究概览

简要总结

Tacrolimus is recommended to be the first line therapeutic medication within the several immunosuppressive agents when treating refractory pediatric nephrotic syndrome, because of its definite efficacy and low toxicity. But there are still some key problems which hinder the using of tacrolimus in clinic, such as its narrow therapeutic widow, great individual difference of pharmacokinetics. Routine therapeutic drug monitoring(TDM) is needed in practice. But the disadvantage of TDM is hysteresis, which could lead to treatment failure or toxicity. To find out the reasons of great pharmacokinetic difference between patients and find out the individual proper dosage before administration are important for the clinical using of tacrolimus.

It is hot in research of tacrolimus in organ transplant field, such as the association between gene polymorphisms of cytochrome P-450 3A4, 3A5 and multiple drug resistant gene(MDR1) and concentration of tacrolimus. However, there is few study about pharmacogenomics and metabonomics of tacrolimus in patients of nephrotic syndrome.

The aim is to study the relationships between pharmacogenomics, metabonomics of tacrolimus and its efficacy, toxicity and blood concentration in patients of nephrotic syndrome, to find out the exact dosage before administration, to provide reference to individual drug administration.

详细描述

Investigators will collect data about efficacy and adverse drug reaction(ADR) such as time of efficacy when evaluated, how to evaluate ADR, data of demography, etc.

研究设计

研究类型
Observational

入排标准

年龄范围
1 Month 至 14 Years(Child)
性别
All
接受健康志愿者

入选标准

  • patients with refractory nephrotic syndrome;
  • patients age ≤14y.

排除标准

  • patients are sensitive to steroid;
  • combined therapy with other immunosuppressive agent;
  • combined using drugs which maybe interact the concentration of tacrolimus;
  • with other malignant disease, such as tumor.

结局指标

主要结局

"Genotypes as measured by polymerase chain reaction-restriction fragment length polymorphism"

时间窗: 1 week

genotype are collected from hospital system.

"Concentration as measured by liquid chromatography mass spectrometry"

时间窗: 1 week

concentration of tacrolimus are collected from hospital system.

"Relationship between genotypes and concentration as analyzed at 1 week"

时间窗: 1 week

using Statistic Package for Social Science 21.0 software to analyze the relationship between gene polymorphism and concentration.

次要结局

未报告次要终点

研究者

发起方
Guangzhou Women and Children's Medical Center
申办方类型
Other
责任方
Principal Investigator
主要研究者

Mo Xiaolan

Clinical Pharmacist

Guangzhou Women and Children's Medical Center

研究点 (1)

Loading locations...

相似试验